Oral aspects of Crohn's disease

International Dental Journal

Volumn 52, Issue 3, 2002, Pages 163-172

  Scheper, H J ^a   Brand, H S ^a,b  

^a Acad Centre for Dentistry Amsterdam ^*

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Crohn's disease; Dental management; Inflammatory bowel disease; Oral pathology

Indexed keywords

CROHN DISEASE; DENTAL CARE; DENTAL CARIES; GINGIVITIS; HUMAN; MOUTH DISEASE; MOUTH MUCOSA; PATHOLOGY; PERIODONTITIS; REVIEW; SALIVA; SECRETION;

CROHN DISEASE; DENTAL CARE FOR CHRONICALLY ILL; DENTAL CARIES; GINGIVITIS; HUMANS; MOUTH DISEASES; MOUTH MUCOSA; PERIODONTITIS; SALIVA;

EID: 0036598794     PISSN: 00206539     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1875-595X.2002.tb00622.x     Document Type: Article

References (74)

1. de Dombal F T. The epidemiology of inflammatory bowel disease. In de Dombal F T, Myren J, Bouchier I A D, et al. (ed). Inflammatory bowel diseases. 2nd ed. pp 96-126. New York: Oxford University Press, 1993.
2. Glickman R M. Inflammatory bowel disease: ulcerative colitis and Crohn's disease. In Fauci A S, Braunwald E, Isselbacher K J, et al (eds). Harrison's principles of internal disease. 14th ed. pp 1633-1645. New York: McGraw-Hill, 1998.
3. Rees T D. Orofacial granulomatosis and related conditions. Periodontology 2000 1999 21: 145-157.
4. Long R G, Cooper B T. Gastrointestinal disease. In: Souhami RL, Moxham J (ed). Textbook of medicine. 3rd ed. pp 657-664. London: Churchill Livingstone, 1997.
5. Wakefield A J, Pittilo R M, Sim R, et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993 39: 345-353.
6. Ekbom A, Wakefield A J, Zack M, et al. Perinatal measles infection and subsequent Crohn's disease. Lancet 1994 344: 508-510.
7. Fisher N C, Yee L, Nightingale P, et al. Measles virus serology in Crohn's disease. Gut 1997 41: 66-69.
8. ter Meulen V. Measles virus and Crohn's disease: view of a medical virologist. Gut 1998 43: 733-734.
9. Rampton D S. Management of Crohn's disease. Brit Med J 1999 319: 1480-1485.
10. Tysk C. Genetic susceptibility in Crohn's disease: review of clinical studies. Eur J Surg 1998 164: 893-896.
11. Reif S, Klein I, Lubin F, et al. Preillness dietary factors in inflammatory bowel disease. Gut 1997 40: 754-760.
12. Russel M G, Engels L G, Muris J W, et al. 'Modern life' in the epidemiology of inflammatory bowel disease: a casecontrol study with special emphasis on nutritional factors. Eur J Gastroenterol Hepatol 1998 10: 243-249.
13. Dupuy A, Cosnes J, Revuz J, et al. Oral Crohn disease: clinical characteristics and long-term follow-up of 9 cases. Arch Dermatol 1999 135: 439-442.
14. Sullivan S N. Hypothesis revisited: toothpaste and the cause of Crohn's disease. Lancet 1990 336: 1096-1097.
15. Pallone F, Monteleone G. Interleukine 12 and Th1 responses in inflammatory bowel disease. Gut 1998 43: 735-736.
16. MacDonald T T, Monteleone G, Pender S L F. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol 2000 51: 2-9.
17. Veloso F T, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel diseases: a prospective study of 792 patients. J Clin Gastroenterol 1996 23: 29-34
18. Bjarnason I, Macpherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997 40: 228-233.
19. Frey F J. Cyclosporine in autoimmune diseases. Schweiz Med Wochenschr 1990 120: 772-786.
20. Hawthorne A B. Methotrexate: a useful alternative in Crohn's disease? Gut 2001 49: 9-10.
21. Rampton D S. Methotrexate in Crohn's disease. Gut 2001 48: 790-791.
22. Mahadevan U, Sandborn W J. Infliximab for the treatment of orofacial Crohn's disease, Inflamm Bowel Dis 2001 7: 38-42.
23. Bell S, Kamm M A. Antibodies to tumour necrosis factor as treatment for Crohn's disease. Lancet 2000 355: 858-860.
24. Sartor R B. New therapeutic approaches to Crohn's disease. N Engl J Med 2000 342: 1664-1666.
25. Dudeney T P. Crohn's disease of the mouth. Proc R Soc Med 1969 62:1237.
26. Basu M K, Asquith P, Thompson R A, et al. Oral manifestations of Crohn's disease. Gut 1975 16: 249-254.
27. Greenstein A J, Janowitz H D, Sachar D B. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976 55: 401-412.
28. Williams A J, Wray D, Ferguson A. The clinical entity of orofacial Crohn's disease. Q J Med 1991 79: 451-458.
29. Lisciandrano D, Ranzi T, Carrasi A, et al. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996 91: 7-10.
30. Pittock S, Drumm B, Fleming P, et al. The oral cavity in Crohn's disease. J Pediatr 2001 138: 767-771.
31. Barnard K M, Walker-Smith J A. Prevalence of oral manifestations of inflammatory bowel disease in a paediatric population. J Deat Res 1994 73: 835 (Abs 388).
32. Bishop R P, Brewster A C, Antonioli D A. Crohn's disease of the mouth. Gastroenterology 1972 62: 302-306.
33. Scully C, Cochran K M, Russell R I, et al. Crohn's disease of the mouth: an indicator of intestinal involvement. Gut 1982 23: 198-201.
34. Talbot T, Jewell L, Schloss E, et al. Cheilitis antedating Crohn's disease: case report and literature update of oral lesions. J Clin Gastroenterol 1984 6: 349-354.
35. Schnitt S J, Antonioli D A, Jaffe B, et al. Granulomatous inflammation of minor salivary gland ducts: a new oral manifestation of Crohn's disease. Hum Pathol 1987 18: 405-407.
36. Field E A, Tyldesley W R. Oral Crohn's disease revisited: a 10-year-review. Br J Oral Maxillofac Surg 1989 27: 114-123.
37. Stricker T, Braegger C P. Oral manifestations of Crohn's disease. N Engl J Med 2000 342: 1644.
38. Challacombe S J. Oro-facial granulomatosis and oral Crohn's disease: are they specific diseases and do they predict systemic Crohn's disease? Oral Dis 1997 3: 127-129.
39. Asquith P, Thompson R A, Cooke W T. Oral manifestations of Crohn's disease. Gut 1975 16: 1249-1254.
40. Sundh B, Hulten L. Oral status in patients with Crohn's disease. Acta Chir Scand 1982 148: 531-534.
41. Halme L, Meurman J H, Laine P, et al. Oral findings in patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol 1993 76: 175-181.
42. Tremaine W J. Treatment of erythema nodosum, aphthous ulcerations. Inflamm Bowel Dis 1998 4: 68-69.
43. Plauth M, Jenss H, Meyle J. Oral manifestations of Crohn's disease: an analysis of 79 cases. J Clin Gastroenterol 1991 13: 29-37.
44. Meurman J H, Halme L, Laine P, et al. Gingival and dental status, salivary acidogenic bacteria and yeast counts of patients with active or inactive Crohn's disease. Oral Surg Oral Med Oral Pathol 1994 77: 465-468.
45. Soames J V, Southam J C. Oral pathology. 3rd ed, pp 231-244. Oxford: Oxford University Press, 1998
46. Gugler R,Jensen J C, Schulte H, et al. The course of Crohn's disease and the side effect profile with long-term treatment using metronidazole. Z Gastroenterol 1989 27: 676-682.
47. Keohane S G, Hayes P C, Hunter J A A. Lichen planus and Crohn's disease. Acta Derm Venereal 1997 77: 488
48. Sandborn J W, Hanauer S B. Antitumor necrosis factor therapy for inflammatory bowel disease. Inflamm Bowel Dis 1999 5: 119-133.
49. Bricker S L, Langlais R P, Miller C S. Gastrointestinal system. In Bricker S L, Langlais R P, Miller C S(ed). Oral diagnosis, oral medicine and treatment planning. 2nd ed. pp 256-299. Philadelphia: Lea and Febiger, 1994.
50. Issa M A. Crohn's disease of the mouth. A case report Br Dent J 1971 130: 247-248.
51. Crama-Bohbouth G, Bosman F T, Vermeer B J, et al. Immunohistological findings in lip biopsy specimens from patients with Crohn's disease and healthy subjects. Gut 1983 24: 202-205.
52. Ghandour K, Issa M. Oral Crohn's disease with late intestinal manifestations. Oral Surg Oral Med Oral Pathol 1991 72: 565-567.
53. Rooney T P. Dental caries prevalence in patients with Crohn's disease. Oral Sarg 1984 57: 623-624.
54. Sundh B, Emilson C G. Salivary and microbial conditions and dental health in patients with Crohn's disease; a 3-year study. Oral Surg Oral Med Oral Pathol 1989 67: 286-290.
55. Sundh B, Johansson I, Emilson C G, et al. Salivary antimicrobial proteins in patients with Crohn's disease. Oral Surg Oral Med Oral Pathol 1993 76: 564-569.
56. Järnerot G, Järnmark I, Nilsson K. Consumption of refined sugar by patients with Crohn's disease, ulcerative colitis, or irritable bowel syndrome. Scand J Gastroenterol 1983 18: 999-1002.
57. Ansaldi N, Morabito A, Balocco P, et al. Dental changes in children with malabsorption. Minerva Pediatr 1989 41: 581-585.
58. Bevenius J. Caries risk in patients with Crohn's disease: a pilot study. Oral Surg Oral Med Oral Pathol 1988 65: 304-307.
59. Lamster I B, Sonis S, Hannigan A, et al. An association between Crohn's disease, periodontal disease and enhanced neutrophil function. J Periodontol 1978 49: 475-479.
60. Engel L D, Pasquinelli K L, Leone S A, et al. Abnormal lymphocyte profiles and leukotriene B4 status in a patient with Crohn's disease and severe petiodontitis. J Periodontol 1988 59: 841-847.
61. Flemmig T F, Shanahan F, Miyasaki K T. Prevalence and severity of periodontal-disease in patients with inflammatory bowel-disease. J Clin Periodontol 1991 18: 690-697.
62. van Dyke T H, Dowell V R, Offenbacher S, et al. Potential role of microorganisms isolated from periodontal lesions in the pathogenesis of inflammatory bowel disease. Infect Immun 1986 53: 671-677.
63. Curran F T, Youngs D J, Allan R N, et al. Candidacidal activity of Crohn's disease neutrophils. Gut 1991 32: 55-60.
64. Siegel M A, Jacobson J J. Inflammatory bowel diseases and the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radial Endod 1999 87: 12-14.
65. Ward C D, Dunphy E P, Jagoe W S, et al. Crohn's disease limited to the mouth and anus. J Clin Gastroenterol 1985 7: 516-521.
66. Crama-Bohbouth G, Lems-van Kan P, Weterman I T, et al. Immunological findings in whole and parotid saliva of patients with Crohn's disease and healthy controls. Dig Dis Sci 1984 29: 1089-1092.
67. Bates T R, Blumenthal H P, Pieniaszek H J. Salivary excretion and pharmacikinetics of sulfapyridine after sulfasalazine. Clin Pharmacol Ther 1977 22: 917-922.
68. Day J M, Houston J B. Saliva:plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease. Br J Clin Pharmacol 1980 9: 91-94.
69. Dhote R, Bergmann J F, Leglise P, et al. Orocecal transit-time in humans assessed by sulfapyridine appearance in saliva after sulfasalazine intake. Clin Pharmacol Ther 1995 57: 461-470.
70. Lebwohl M, Lebwohl O. Cutaneous manifestations of inflammatory bowel disease. Inflamm Bowel Dis 1998 4: 142-148.
71. Winter H S. Treatment of pyoderma gangrenosum, erythema nodosum, and aphrhous ulcerations. Inflamm Bowel Dis 1998 4: 71
72. Weinstein T A, Sciubba J J, Levine J. Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease. J Pedtatr Gastroenterol Nutr 1999 28: 214-216.
73. Casson D H, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and penneal Crohn's disease. Gut 2000 47: 436-440.
74. Malins T J, Wilson A, Ward-Booth R P. Recurrent buccal space abscesses: a complication of Crohn's disease. Oral Surg Oral Med Oral Pathol 1991 72: 19-21.